Novel Hybrid Series of Compound Derived from 2-Aminotetralin and Piperazine Based Derivatives: Characterization for D1, D2, D3, D4 and other Serotonin Receptor Subtypes Binding

Published date: May 6, 2010

Technology description

A series of compounds derived from 2-aminotetralin and piperazine fragments have been synthesized, which exhibit high CNS activity in vivo and in vitro. Some of the selected lead compounds have exhibited potent in vivo activity in a Parkinson?s disease animal model with long extended duration of action. In particular, these compounds show high D3 receptor affinity and/or high D3/D2 selectivity. In addition to the potential therapeutic treatment of Parkinson?s disease and depression, these novel compounds have possible application in the treatment of a number of other neurological disorders such as cocaine addiction, restless leg syndrome or as an atypical antipsychotic agent.

Application area

·Atypical Antipsychotics
·Medication for Neurodegenerative Diseases
·Anti-depressants
·Treatment of Addiction

Institution

Wayne State University

Inventors

Aloke Dutta
Professor
Pharmaceutical Sciences
Xiang-Shu Fei
Post Doctoral Associate

联系我们

叶先生

电 话：021-65679356

手 机：13414935137

邮 箱：yeyingsheng@zf-ym.com